New cocktail aims to wake up sleeping HIV

NCT ID NCT07635992

Not yet recruiting Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether combining two drugs—ibalizumab and chidamide—can safely reduce the hidden HIV reservoir in people living with HIV. The study will enroll up to 29 adults on stable antiretroviral therapy. Researchers will monitor side effects and measure changes in HIV DNA levels in blood cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ibalizumab (monoclonal antibody) and chidamide (histone deacetylase inhibitor)
What this could lead to: If successful, this could point toward a strategy to reduce hidden HIV reservoirs, potentially allowing people with HIV to manage the virus without lifelong daily medication.
What could go wrong: This is a very early Phase 1 trial with only 18-29 participants. It primarily tests safety, not effectiveness. The combination may cause side effects or fail to shrink the viral reservoir significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV (HUMAN IMMUNODEFICIENCY VIRUS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV (HUMAN IMMUNODEFICIENCY VIRUS)

More trials for these conditions

Other studies related to the condition(s) this trial covers.